Crystalline form of benzylbenzene SGLT2 inhibitor
US8987323B2 · kind B2 · utility
13Cited by
20References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 13, 2011 |
| Grant date | Mar 24, 2015 |
| Priority date | — |
| Expiry date | May 14, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H7/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.